NanoViricides' NV-387 Emerges as Potential Solution to Escalating Measles Outbreaks

NanoViricides, Inc. (NYSE American: NNVC) has spotlighted its drug candidate NV-387 as a potential breakthrough in combating the surge of measles cases across the United States, Canada, the UK, and the European Union. With measles cases in the U.S. hitting 1,319 in 2025, exceeding the 2019 record, and Canada reporting over 3,800 cases, the urgency for effective treatments has never been higher. The World Health Organization's report of 127,350 cases in Europe in 2024, the highest since 1997, further underscores the global challenge posed by this preventable disease.

NV-387, developed using NanoViricides' host-mimetic nanomedicine technology, has demonstrated both effectiveness and safety in animal studies involving humanized h-CD150+ knock-in mice. The completion of a Phase I clinical trial with no adverse events marks a significant milestone, indicating the drug's strong tolerability in humans. This positions NV-387 as a frontrunner in the race to address the critical medical need for an approved measles treatment, especially in light of vaccination hesitancy and immune dysfunction challenges.

The potential for NV-387 to qualify for Orphan Drug and Fast Track designations could expedite its approval process, offering up to seven years of market exclusivity. This development is particularly noteworthy given the absence of any approved drugs for measles, highlighting NV-387's role in filling a vital gap in antiviral therapies. For more details on NanoViricides' announcement, visit https://ibn.fm/w2BR6.

As NanoViricides advances NV-387 into Phase II clinical trials, the global health community watches closely. The drug's broad-spectrum antiviral capabilities not only offer hope for measles but also for other respiratory viral infections, including RSV, COVID-19, and influenza. This positions NanoViricides at the forefront of innovative antiviral research, with the potential to significantly impact public health outcomes worldwide.